REVEAL GENOMICS

#ASCO25 | Pre-operative THP leads to pCR in 2/3 of early-stage HER2+ ER- breast cancer patients. Nadine Tung, MD, presents June 2, 3:24–3:36 PM CDT | Hall B1 @EAonc @theNCI @BCRFcure @SusanGKomen #BCSM #HER2DX @RevealGenomics @BIDMChealth ECOG-ACRIN EA1181 bit.ly/CompassHER2-pC…

Feliç Dia de Sant Jordi! #SantJordi2025 #HER2DX #precisiononcology #innovation

Com pot la IA ajudar a millorar el diagnòstic del càncer? @patri0608 de @RevealGenomics i Xavier Dumont de @barcelonactiva comparteixen els seves aplicacions al #RevolucióCatRàdio 3cat.cat/3cat/reveal-ge…

Our co-founder & CSO, @prat_aleix on precision oncology at @iesebschool : "We need a 360-degree view with all stakeholders to implement the precision medicine" Thanks, #IESEStudentClub, for an inspiring MBA Healthcare Day 2025!

Moltes gràcies @VIAEmpresa i a #AnaMariaGonzálezFranco per aquest article en què la nostra cofundadora i CEO @patri0608 parla dels inicis de la companyia amb el suport de @barcelonactiva, del nostre test #HER2DX, així com del futur que ens espera. ow.ly/TiMS50VpF3Z

🔴 Happening now! @esther_sanfeliu presents the correlation of the #HER2DX genomic test with pathologic features in early-stage HER2+ #breastcancer at @TheUSCAP. #HER2DX offers biological insights beyond standard pathology, potentially enhancing personalized treatment.

How much does a cancer treatment cost? How does it affect patients and healthcare national systems? ⬇️ ow.ly/3sJZ50VnCB9

On another great day for #HER2DX at @SG_BCC Dr. #MafaldaOliveira from @_SOLTI discusses @DefinitiveTrial , the first prospective #HER2DX trial across 44 hospitals in 7 countries. #SGBCC2025 #breastcancer #precisiononcology

@RenoHemonc @stolaney1 @SG_BCC @Prof_Nadia_H Please contact us; we will be glad to provide this information.

@stolaney1 @SG_BCC @Prof_Nadia_H Her2DX available commercially?

Wonderful talk by Nadia Harbeck on treatment approaches for early stage HER2+ BC--> nice work on tailoring therapy to the individual patient @SG_BCC #bcsm @Prof_Nadia_H

📢 New study on HER2DX in early-stage HER2+ breast cancer! 🎉 🔹 48% had treatment changes, 73% with reduced therapy. 🔹 Less intense treatment in 69 pCR-high patients matched multi-agent chemo’s pCR rates. 👉🏻esmorwd.org/action/showPdf… 💡#BreastCancer #HER2Positive #Genomics

HER2DX, a genomic diagnostic test, helped identify patients with early-stage HER2-positive breast cancer with a higher likelihood of achieving a pathological complete response. #bcsm | @OlgaMartnezSez1 cancernetwork.com/view/genomic-a…

🗞️ Un estudio coliderado por INCLIVA y el @hospitalclinic-@idibaps confirma el impacto clínico de la prueba genómica HER2DX® en el cáncer de mama HER2+ en etapas tempranas 🔗 incliva.es/un-estudio-en-…

Today, we honor the incredible contributions of women in every field, every community, and every part of the world. It’s a day to acknowledge progress, recognize challenges, and continue working toward a future built on equality. #IWD #InternationalWomensDay

Muchas gracias @Circuloecuestre y @FundacionFero por ofrecer un espacio para explicar la oncología de precisión de la mano de nuestro CSO y co-founder @prat_aleix en la Charla “Presente y futuro del cáncer” llevada a cabo ayer. ¡Enhorabuena por esta iniciativa!

💫💫💫

🚨 ¿Todavía no has escuchado el caso de @RevealGenomics?

Our work isn’t just about innovation—it’s about impact. We are dedicated to developing cutting-edge diagnostic tools that help define the best therapeutic options for patients with cancer, helping them receive the most effective treatment. #WorldCancerDay #precisiononcology

💫 Proud to share that we have achieved ISO 27001 Certification! Our CTO, @Laiapb, remarks: "This certification reinforces our commitment to data security, confidentiality, and integrity at the highest international standards." Huge thanks to our team for making it happen! 🙌🏻

Moltes gràcies, @barcelonactiva, per convidar-nos a la xerrada "T'acostem a empreses disruptives i innovadores que estan redefinint el mercat laboral", en la qual Ángeles Sebastián, COO, ha parlat dels nous perfils necessaris que ens ajudaran a revolucionar l'#oncologiadeprecisió

Announcing a link between B-cell and T-cell immune infiltration and improved survival rates in #breastcancer survivors. These are integrated into #HER2DX and #TNBCDX, enhancing their role in guiding clinical decisions for HER2+ and TNBC. More: ow.ly/Yk5450UFbNw